New Data Highlights Promising Treatment Advances

BeOne Medicines has revealed significant advancements in B-cell cancer treatments at the European Hematology Association (EHA) 2026 Congress in Stockholm. These advancements demonstrate promising results for both early and advanced stages of disease, highlighting the potential for new therapeutic approaches.

Updated data from tacabrutideg (BGB-16673), a Bruton’s tyrosine kinase (BTK) degrader, show durable responses in relapsed and refractory (R/R) chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). The study involved 67 patients with R/R CLL/SLL, including those with high-risk disease features such as del(17p)/TP53 mutation and BTK inhibitor resistance mutations.

The analysis reported an overall response rate (ORR) of 85.1% and a median time to first response (TTFR) of 2.8 months. the median duration of response (DOR) was 20.7 months, and the 24-month progression-free survival (PFS) rate was 53.8%. Tacabrutideg was well tolerated in this heavily pretreated population, with no treatment-related deaths.

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, at BeOne Medicines, stated, "BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forward. Tacabrutideg is showing durable responses in heavily pretreated CLL, where patients have limited options."

Combination Therapy Shows High Efficacy

The combination of BRUKINSA (zanubrutinib) and BEQALZI (sonrotoclax) demonstrated high rates of undetectable minimal residual disease (uMRD) in treatment-naïve CLL and R/R mantle cell lymphoma (MCL). This reinforces its potential as a fixed-duration, all-oral treatment.

In treatment-naïve CLL patients, the combination achieved a 100% overall response rate (ORR), with 59.5% attaining complete responses. In relapsed/refractory CLL, the ORR was also 100%, with a 52% complete response rate.

Stephan Stilgenbauer, Professor of Medicine at Ulm University, noted, "Tacabrutideg achieved durable responses even in patients with high-risk characteristics, suggesting a promising new approach for patients with limited options."

Further insights will be shared during oral and poster presentations at the EHA 2026. These will include detailed analysis of tacabrutideg's performance in BTK inhibitor-naïve patients and its potential for earlier treatment lines.

The oral presentation, selected for inclusion in the EHA Press programme, will highlight data from the CaDAnCe-101 study. This study shows tacabrutideg's durable responses in heavily pretreated R/R CLL/SLL and R/R WM, with presentations scheduled for June 13 and 14.